NCT03724526 (TEACH) is a NA clinical trial of Text messaging in Type 2 Diabetes Mellitus, sponsored by Nanfang Hospital, Southern Medical University.

Who is sponsoring NCT03724526?

NCT03724526 is sponsored by Nanfang Hospital, Southern Medical University.

What drugs are being tested in NCT03724526?

Interventions in NCT03724526: Text messaging.

What condition does NCT03724526 study?

NCT03724526 studies Type 2 Diabetes Mellitus.

Is NCT03724526 still recruiting?

NCT03724526 is currently completed. Last updated 24 October 2022.

Last reviewed 2022-10-24 · How we verify

NCT03724526: TEACH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Text Messaging and Cardiovascular Health in Diabetes Mellitus

Completed NA Last updated 24 October 2022

What this trial tests

NA trial testing Text messaging in Type 2 Diabetes Mellitus in 819 participants. Completed in 30 July 2022.

Timeline

1 November 2018

Primary endpoint
22 June 2022

30 July 2022

Quick facts

Lead sponsor	Nanfang Hospital, Southern Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	819
Start date	1 November 2018
Primary completion	22 June 2022
Estimated completion	30 July 2022
Sites	1 location across China

Drugs / interventions tested

Text messaging

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →

Sponsor

Nanfang Hospital, Southern Medical University

Who can join

Adults 18 to 80, any sex, with Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study of the proposed randomized trial is to evaluate the effectiveness of automated mobile phone text message-based intervention in improving lifestyle modification, medication adherence and CVD risk factors (glycated hemoglobin \[HbA1C\], systolic blood pressure \[SBP\], and LDL-cholesterol) over 12 months among patients with type 2 diabetes.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
Palmer MJ, Machiyama K, Woodd S, Gubijev A, et al · · 2021 · cited 25× · PMID 33769555 · DOI 10.1002/14651858.cd012675.pub3
Mobile App-Based Intervention and Cardiovascular Risk Factors in Patients With Uncontrolled Type 2 Diabetes: A Randomized Clinical Trial.
Zhang PZ, Guo D, Liu CQ, Chen N, et al · · 2025 · PMID 40892411 · DOI 10.1001/jamanetworkopen.2025.29762

Verify or expand the search:

Other trials of Text messaging

Trials testing the same drug.

NCT06624332 — Home Visitation Enhancing Linkages Project in Kansas · NA · not yet recruiting
NCT06747780 — Text Messaging Intervention on Happy Family Meal for Improving Family Communication and Well-being in Hong Kong Adults · NA · not yet recruiting
NCT06319885 — Text Messaging to Reduce High-risk Alcohol Use Among Older Adults · NA · recruiting
NCT05852054 — Supporting Transitions to Primary Care Among Under-resourced, Postpartum Women (STEP-UP) · Phase 3 · active not recruiting
NCT05537441 — Precision Vaccine Promotion in Underserved Populations · NA · completed

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other Nanfang Hospital, Southern Medical University trials

Trials by the same sponsor.

NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03724526 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
Last refreshed: 24 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03724526.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing